IP3R Calcium Signaling Biomarker for Early ASD Risk Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for autism spectrum disorder (ASD) are limited by the lack of a reliable biomarker and effective therapeutic targets, with existing genetic tests being costly and ambiguous, and behavioral assessments being subjective, leading to a need for early and objective diagnostic tools.
Innovation Solution
The use of inositol trisphosphate receptor (IP3R) free calcium (Ca2+) signaling activity in cultured cells, measured using a Ca2+ fluorescent probe, to diagnose ASD risk, identify therapeutic agents, and monitor treatment response, leveraging skin fibroblasts and specific agonists for early quantitative diagnosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of information
If genetic tests are used for ASD diagnosis, then diagnostic information can be obtained, but the tests are costly and produce ambiguous results
Solution Approach 1:
The patent replaces complex genetic sequencing analysis with a functional assay measuring IP3R calcium signaling activity. Instead of analyzing multiple genetic loci and their ambiguous contributions, the invention uses a direct functional readout of cellular calcium release in response to IP3, providing a clear quantitative measure that reflects the downstream functional impact of genetic variations on ASD risk.
Solution Approach 2:
The invention shifts from measuring genetic presence/absence to measuring functional signaling intensity. By quantifying calcium release magnitude, kinetics, and temporal patterns, the assay transforms ambiguous genetic data into precise functional parameters that directly correlate with ASD susceptibility and can guide treatment decisions.
2Loss of information
If behavioral assessments are used for ASD diagnosis, then diagnostic evaluation can be performed, but the assessments are subjective and lack objectivity
Solution Approach 1:
The patent replaces subjective behavioral observation with an objective in vitro functional assay. The calcium signaling measurement provides quantifiable data through fluorescence intensity, kinetic parameters, and temporal patterns that are independent of observer interpretation, eliminating subjectivity inherent in behavioral assessments.
Solution Approach 2:
The assay uses the patient's own cultured cells to perform the diagnostic test, allowing the biological system itself to provide the diagnostic information. The functional readout of calcium signaling in the patient's cells directly reflects their neurodevelopmental status without requiring external interpretation or comparison to behavioral norms.
3Loss of time
If current diagnostic methods are used, then diagnosis can be made, but early and objective diagnostic tools are lacking
Solution Approach 1:
The patent enables preliminary diagnostic assessment by measuring functional calcium signaling in cells cultured from early childhood samples. This functional assay can be performed on archived samples or new cultures, providing early diagnostic information that precedes traditional behavioral diagnosis, allowing for earlier intervention planning while maintaining objective reliability through quantitative measurement.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Provides a functional biomarker for early and objective ASD diagnosis, enabling effective treatment strategies and therapeutic agent identification through quantitative analysis of IP3R Ca2+ signaling.
Implementation Method 1
measuring the level of IP3R Ca2+ signaling activity in both sets of the cultured cells from (c) in response to an agonist of IP3R Ca2+ signaling using a Ca2+ fluorescent probe and measuring the amount of fluorescence emitted by the probe
Data Source
AI summary
Methods of detecting the level of inositol trisphosphate receptor (IP3R) free calcium (Ca2+) signaling activity in the cultured cells induced by an agonist of IP3R Ca2+ signaling are described herein. The detection of IP3R Ca2+ signaling allows for diagnosing the risk of a patient or subject for developing an Autism Spectrum Disorder (ASD). Additionally, methods described herein could be used for identifying potential therapeutic anti-ASD agents. The methods for treatment and monitoring of the disease are also outlined.